Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more
Ocugen Inc (OCGN) - Total Assets
Latest total assets as of September 2025: $57.60 Million USD
Based on the latest financial reports, Ocugen Inc (OCGN) holds total assets worth $57.60 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ocugen Inc - Total Assets Trend (2012–2024)
This chart illustrates how Ocugen Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ocugen Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ocugen Inc's total assets of $57.60 Million consist of 74.8% current assets and 25.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Ocugen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ocugen Inc's current assets represent 74.8% of total assets in 2024, an increase from 71.7% in 2012.
- Cash Position: Cash and equivalents constituted 71.0% of total assets in 2024, up from 69.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Ocugen Inc Competitors by Total Assets
Key competitors of Ocugen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Ocugen Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ocugen Inc generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ocugen Inc is currently not profitable relative to its asset base.
Ocugen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.85 | 2.58 | 7.16 |
| Quick Ratio | 1.85 | 2.58 | 7.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.28 Million | $ 24.91 Million | $ 22.26 Million |
Ocugen Inc - Advanced Valuation Insights
This section examines the relationship between Ocugen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 130.17 |
| Latest Market Cap to Assets Ratio | 5.60 |
| Asset Growth Rate (YoY) | 27.7% |
| Total Assets | $82.44 Million |
| Market Capitalization | $461.52 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Ocugen Inc's assets at a significant premium ( 5.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ocugen Inc's assets grew by 27.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ocugen Inc (2012–2024)
The table below shows the annual total assets of Ocugen Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $82.44 Million | +27.72% |
| 2023-12-31 | $64.55 Million | -40.58% |
| 2022-12-31 | $108.63 Million | +2.71% |
| 2021-12-31 | $105.76 Million | +286.33% |
| 2020-12-31 | $27.38 Million | +62.88% |
| 2019-12-31 | $16.81 Million | -3.56% |
| 2018-12-31 | $17.43 Million | +57.93% |
| 2017-12-31 | $11.04 Million | -69.41% |
| 2016-12-31 | $36.08 Million | -1.92% |
| 2015-12-31 | $36.79 Million | -43.84% |
| 2014-12-31 | $65.50 Million | +342.68% |
| 2013-12-31 | $14.80 Million | -29.69% |
| 2012-12-31 | $21.04 Million | -- |